Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPJOHN HOPES TO INTRODUCE MOTRIN IB SINUS BY THE END OF 1993

This article was originally published in The Tan Sheet

Executive Summary

UPJOHN HOPES TO INTRODUCE MOTRIN IB SINUS BY THE END OF 1993 pending approval from FDA. Motrin IB Sinus would be the first symptom-specific product in the Motrin IB line. Upjohn currently markets Motrin IB (ibuprofen) caplets and tablets. The company is understood to be seeking a number of indications for Motrin IB Sinus including pain relief, fever reduction and nasal decongestion. The product will contain ibuprofen 200 mg and pseudoephedrine 30 mg. Other products on the market with the ibuprofen/pseudoephedrine combination include Whitehall's Advil Cold & Sinus and Dristan Sinus and Robins' Dimetapp Sinus. Upjohn anticipates that Motrin IB Sinus, if cleared, will be offered in both coated caplets and coated tablets. The ad agency of record for the existing Motrin IB line is Southfield, Mich.- based W. B. Doner & Company.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel